Risk of neutropenia in a clozapine-treated elderly population

Schizophrenia Research

Volumn 148, Issue 1-3, 2013, Pages 183-185

  Guenette, Melanie D ^a   Powell, Valerie ^c   Johnston, Kimberly ^c   Foussias, George ^a,b,c   Agid, Ofer ^b,c   Hahn, Margaret ^b,c   Takeuchi, Hiroyoshi ^b,c   Remington, Gary ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RISPERIDONE;

ADULT; AGED; AGRANULOCYTOSIS; ALCOHOLISM; CANADA; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE REGISTRY; FEMALE; GERIATRIC PATIENT; HEMATOLOGIC DISEASE; HUMAN; LETTER; MALE; MEDICAL HISTORY; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT IDENTIFICATION; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT;

AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 84881025869     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.05.001     Document Type: Letter

References (17)

1. Athanasiou M.C., Dettling M., Cascorbi I., Mosyagin I., Salisbury B.A., Pierz K.A., Zou W., Whalen H., Malhotra A.K., Lencz T., Gerson S.L., Kane J.M., Reed C.R. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J. Clin. Psychiatry 2011, 72(4):458-463.
2. Barak Y., Wittenberg N., Naor S., Kutzuk D., Weizman A. Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. Compr. Psychiatry 1999, 40(4):320-325.
3. Bastiampillai T., Dhillon R., French T.H. Clozapine use in treatment-resistant agitation in the setting of dementia. Aust. N. Z. J. Psychiatry 2009, 43(7):689-690.
4. Bowskill S., Couchman L., MacCabe J.H., Flanagan R.J. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65years and over: data from a therapeutic drug monitoring service, 1996-2010. Hum. Psychopharmacol. 2012, 27(3):277-283.
5. Canadian Pharmacists Association C.P. Compendium of Pharmaceuticals and Specialities (CPS) 2012, CPA, Ottawa.
6. Chowdhury N.I., Remington G., Kennedy J.L. Genetics of antipsychotic-induced side effects and agranulocytosis. Curr. Psychiatry Rep. 2011, 13(2):156-165.
7. Dale D.C. Advances in the treatment of neutropenia. Curr. Opin. Support. Palliat. Care 2009, 3(3):207-212.
8. Herst L., Powell G. Is clozapine safe in the elderly?. Aust. N. Z. J. Psychiatry 1997, 31(3):411-417.
9. Ismail Z., Wessels A.M., Uchida H., Ng W., Mamo D.C., Rajji T.K., Pollock B.G., Mulsant B.H., Bies R.R. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am. J. Geriatr. Psychiatry 2012, 20(1):53-60.
10. Kanaan R.A., Kerwin R.W. Lithium and clozapine rechallenge: a retrospective case analysis. J. Clin. Psychiatry 2006, 67(5):756-760.
11. Lee H.B., Hanner J.A., Yokley J.L., Appleby B., Hurowitz L., Lyketsos C.G. Clozapine for treatment-resistant agitation in dementia. J. Geriatr. Psychiatry Neurol. 2007, 20(3):178-182.
12. Munro J., O'Sullivan D., Andrews C., Arana A., Mortimer A., Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br. J. Psychiatry 1999, 175:576-580.
13. O'Connor D.W., Sierakowski C., Chin L.F., Singh D. The safety and tolerability of clozapine in aged patients: a retrospective clinical file review. World J. Biol. Psychiatry 2010, 11(6):788-791.
14. Remington G., Agid O., Foussias G., Ferguson L., McDonald K., Powell V. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?. Psychopharmacology (Berl) 2013, 225(3):505-518.
15. Snowdon J., Halliday G. A study of the use of clozapine in old age psychiatry. Int. Clin. Psychopharmacol. 2011, 26(4):232-235.
16. Suzuki T., Remington G., Uchida H., Rajji T.K., Graff-Guerrero A., Mamo D.C. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs Aging 2011, 28(12):961-980.
17. Weintraub D., Chen P., Ignacio R.V., Mamikonyan E., Kales H.C. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch. Neurol. 2011, 68(7):899-904.